Coagulopathy

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Agency, INN, Allergy, ATC, Antibody, Plasma, Blood, DDAVP, International, Bleeding, Von Willebrand factor, Injection, Headache, Disease, Coagulopathy, Language, Hypersensitivity, European Medicines Agency, Von Willebrand disease, Select, Anatomy, IIA, VWD, Medical device

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

2023 Annual Eric Dostie Memorial College Scholarship Recipients

Retrieved on: 
Monday, November 13, 2023
Memory, Student, Essay, Coagulopathy, Haemophilia, Education

The scholarship was created to honor the memory of 5-year-old Eric Dostie, a boy with hemophilia who was tragically murdered on August 27, 1994.

Key Points: 
  • The scholarship was created to honor the memory of 5-year-old Eric Dostie, a boy with hemophilia who was tragically murdered on August 27, 1994.
  • Patrick M. Schmidt, chief executive officer of FFF Enterprises, said, “I congratulate each of these deserving Eric Dostie Memorial College Scholarship recipients and wish them much success.
  • Applications for the 2024 Eric Dostie Memorial College Scholarship are now open.
  • Visit the Nufactor Eric Dostie Memorial College Scholarship website to learn more about the program.

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, CNS, Hypertension, Cerebral amyloid angiopathy, Hepatocellular carcinoma, Gene, ALN, Cardiomyopathy, RNA interference, IND, Tissue, Liver, Sanofi, Amyloidosis, Gene silencing, Overweight, KHK, Patient, FGF21, CAA, Part, Obesity, T2DM, Neoplasm, Investigational New Drug, Therapy, LNP, Development, Shanda, Growth, HCC, Central nervous system, Type, TTR, Immunotherapy, Polyneuropathy, Haemophilia, Medication, Biology, Coagulopathy, Traffic barrier, Adipose tissue, Vaccine, Medical device, Pharmaceutical industry, Video game, Alnylam Pharmaceuticals, Capella, ATTR

We expect our track record of strong pipeline and commercial execution to continue through the end of 2025 and beyond,” said Akshay Vaishnaw, M.D., Ph.D., Chief Innovation Officer of Alnylam.

Key Points: 
  • We expect our track record of strong pipeline and commercial execution to continue through the end of 2025 and beyond,” said Akshay Vaishnaw, M.D., Ph.D., Chief Innovation Officer of Alnylam.
  • In addition, Alnylam will share an update on delivery advances driving ALN-BCAT, which will soon begin clinical testing in patients with hepatocellular carcinoma (HCC).
  • A peak mean TTR reduction of 97% was achieved at Day 29 and a mean TTR reduction of 93% was sustained at Day 180.
  • The Company’s R&D Day event will be held today, Wednesday, Dec. 13, from 8:30 a.m. to 12:45 p.m.

Survey highlights substantial need for canine osteoarthritis management protocol for veterinarians

Retrieved on: 
Thursday, December 7, 2023
Post-traumatic arthritis, Vomiting, School, PSGAG, Research, Self-assessment, Argyreia nervosa, CCAT, Osteoarthritis, AAHA, Patient, Veterinary medicine, Synovial joint, American Animal Hospital Association, Breeding, Veterinarian, Diarrhea, University, Partnership, Coagulopathy, Knowledge, VMX, Dog, Education, Pharmaceutical industry, Vaccine

SHIRLEY, N.Y., Dec. 7, 2023 /PRNewswire/ -- A pivotal survey by the American Animal Hospital Association (AAHA), conducted in partnership with American Regent Animal Health and leading veterinary orthopedist Denis Marcellin-Little, DEDV, DACVS, DACVSMR, CCAT, has revealed a significant demand among participating veterinarians for a structured protocol to manage canine osteoarthritis, especially when it comes to early detection in younger dogs.

Key Points: 
  • An overwhelming 95% of veterinarians agree that a canine osteoarthritis protocol would be beneficial, signaling an urgent need for standardized care procedures.
  • The survey, which garnered responses from nearly 800 veterinarians, also sheds light on practitioners' self-assessment of their own knowledge.
  • With veterinarians estimating that 45% of their patients have osteoarthritis, 47% are predisposed to it, and 26% have early-onset disease, the survey highlights a critical window of opportunity for early intervention.
  • In addition, veterinarians say 75% of their clients know only "a little bit" about canine osteoarthritis, presenting an opportunity for better education and resources that boost understanding of what dog owners need to know about osteoarthritis.

Octapharma USA: FDA Grants Expanded Approval to wilate® as the First VWF Concentrate for Prophylaxis in All Types of VWD

Retrieved on: 
Tuesday, December 5, 2023
Woman, Research, Safety, Food, Ageing, Disease, Hematology, Patient, Prevalence, FDA, ABR, Caregiver, MD, Bleeding, VWF, Bes, Haemophilia, Coagulopathy, Quality of life, Shriners Hospitals for Children, Observational study, Therapy, Health, VWD, Pharmaceutical industry, Nursing, Birth control

PARAMUS, N.J., Dec. 5, 2023 /PRNewswire/ -- Octapharma USA announced the expansion of the U.S. Food and Drug Administration (FDA) approval for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection. The approved label now includes routine prophylaxis aimed at reducing the frequency of bleeding episodes in adults and children aged 6 and older with any type of von Willebrand disease (VWD), the most prevalent bleeding disorder in the United States. Wilate® is the first von Willebrand factor (VWF) concentrate indicated for prophylactic treatment across all forms of VWD, marking a significant milestone in the field.

Key Points: 
  • Wilate® is the first von Willebrand factor (VWF) concentrate indicated for prophylactic treatment across all forms of VWD, marking a significant milestone in the field.
  • "The approval of wilate® for VWD prophylaxis is a welcome new treatment option that can be life-saving for many patients.
  • Increased use of VWF prophylaxis in VWD patients may lead to improved patient care and a reduced burden of disease."
  • In tandem with this approval, Octapharma USA extends its commitment to patient care through the Factor My Way patient support program.

Bispecific Antibodies: Structural Design, Production and Purification Strategies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 22, 2023
Bispecific monoclonal antibody, Research, Antigen, Toxicity, Knob, GenScript Biotech, Epitope, Infection, Therapy, Cancer, Monoclonal antibody, Autoimmunity, Coagulopathy, Ligand, Vaccine

TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification. BsAbs have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer, chronic inflammatory diseases, autoimmunity, neurodegeneration, bleeding disorders and infections. Currently, there are 12 bispecific antibodies approved worldwide.

Key Points: 
  • Attendees will learn the key considerations of bispecific antibody structural design and analysis of general design strategies.
  • The featured speaker will discuss production strategies and by-product purification plans for bispecific antibodies with different structures.
  • TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification.
  • Join this webinar to gain insights into the diverse applications, design considerations and production strategies of bispecific antibodies.

Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Health, Pharmaceutical, Stroke, Allergy, Headache, Incidence, Thrombosis, Vomiting, Laboratory, Prevalence, Face, Myocardial infarction, Pfizer, Clifton Springs Hospital & Clinic, Research, Bleeding, Nausea, Venous thrombosis, Pulmonary embolism, Abbott Laboratories, Fever, Chest pain, Deep vein thrombosis, DVT, Common, Geography, Marketing, Hospital, Atomic mass, Coagulopathy, Merck Group, Wilford Hall Ambulatory Surgical Center, Intracerebral hemorrhage, USD, Blood, Safety, Patient, Cardiovascular disease, COVID-19, Pharmaceutical industry, Birth control

The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Urokinase Market (2023-2028) by Type, Dose Strength, Indication, Applications, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The urokinase market is being driven by the increasing prevalence of pulmonary embolism (PE), a condition characterized by blood clots in the lungs.
  • Urokinase, a thrombolytic agent, is used to dissolve these clots and is naturally produced by the human body.
  • The urokinase market is highly competitive, featuring numerous players involved in developing and marketing urokinase products.

Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities

Retrieved on: 
Thursday, November 2, 2023
RSV, Historically black colleges and universities, Social media, Black, Sickle cell disease, Physician, PASD, Equity, Navigation, Trust, Quality of life, Vaccination, Caregiver, Clinical trial, Partnership, African Americans, Nursing, Patient, Diagnosis, Coagulopathy, MS, Birth control, Vaccine, BMT, University

KO Flu and Covid will engage and communicate with seniors about influenza risks and the benefits of vaccination by utilizing boxing events in historically disadvantaged communities.

Key Points: 
  • KO Flu and Covid will engage and communicate with seniors about influenza risks and the benefits of vaccination by utilizing boxing events in historically disadvantaged communities.
  • This service will assist patients and caregivers by clarifying treatment options, providing biomarker testing education, and identifying clinical trial options.
  • Transplant Equity and Awareness for Sickle Cell Disease will address low stem cell donation and the underutilization of Bone Marrow Transplant (BMT) treatment.
  • This multi-organization partnership strives to lead an educational awareness program targeting Black and Hispanic communities in the US.

Pathway to Cures Announces Venture Investment in Five Liters

Retrieved on: 
Monday, October 16, 2023
Research, General Health, Pharmaceutical, Philanthropy, Fund Raising, Foundation, Clinical Trials, Science, Biotechnology, Other Philanthropy, Other Science, Health, VNS, MBA, Doctor of Philosophy, Litre, Indian Council of Medical Research, Bleeding, Anemia, Sickle cell disease, MD, Northwell Health, Injury, Von Willebrand disease, VWD, Electricity, Vagus nerve stimulation, Medical research, Desmopressin, Feinstein Institutes for Medical Research, Coagulopathy, Haemophilia, Scientific Advisory Group, Tan, Hemostasis, Nature Communications, Cyclic permutation, Blood, Vagus nerve, Patient, Pharmaceutical industry, Medical device, The New York Times, Cure, Pathway

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.

Key Points: 
  • Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • This significant milestone is made possible through Five Liters' collaboration with Northwell Health’s Feinstein Institutes for Medical Research in New York.
  • Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF) and chairs the Pathway to Cures Scientific Advisory Group.

Pathway to Cures Announces First Donor to Fund

Retrieved on: 
Monday, October 9, 2023
Philanthropy, Health, Other Philanthropy, Fund Raising, Foundation, Pharmaceutical, Biotechnology, Knowledge, Chairperson, Anemia, Haemophilia B, Sickle cell disease, MD, Haemophilia, Coagulopathy, Blood, Life, Quality of life, Pharmaceutical industry

Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation, focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, announces a transformational gift to their fund.

Key Points: 
  • Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation, focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community, announces a transformational gift to their fund.
  • Kim and Scott Martin have made a founding donation to Pathway to Cures venture fund adding to the existing estate gift which launched the fund earlier this year.
  • “My wife and I feel privileged to launch the fundraising efforts for Pathway to Cures.
  • Dr. Valentino is the Chief Executive Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF), “as a donor to the venture fund, Scott will also serve as a member of the Donor Advisory Committee for Pathway to Cures.